Measles IgA ELISA
The IMMUNOLAB Measles IgA Antibody ELISA Test Kit has been designed for the the detection and the quantitative determination of specific IgA antibodies against Measles in serum and plasma. Further applications in other body fluids are possible and can be requested from the Technical Service of IMMUNOLAB.
Measles is a highly contagious viral disease characterized by a clinically distinct prodrome of fever, coryza, conjunctivitis, cough and a pathognomic exanthem (Koplik`s spots). The disease is the result of infection with the Measles Virus, genus Morbillivirus of the family Paramyxoviridae. Ten to twelve days after infection, the most prominent and characteristic prodromal symptoms appear: coryza; a persistant barking cough; keratoconjunctivitis, often with photophobia; and fever. Generally lymphadenopathy and splenomegaly are also frequent. During this period, Koplik`s spots appear on the bucal mucosa that rapidly spread involving the entire mucous membrane. These spots are usually gone by the time the skin rash reaches its peak. The rash of Measles appears after a 3- to 5-days prodrome, some 14 days after exposure. The rash quickly becomes maculopapular and spreads rapidly over the face, neck, trunk and extremities during the next three days. At its height, the eruption has generally deepened to a redish purple and may be associated with edema of the skin. Complications are: otitis media, pneumonia and encephalitis. Measles have a more severe expression in younger or undernourished children with a higher incidence of hemorrhage Measles, with 5% to 10% of lethal cases.
In people that have been vaccinated with inactive virus (before 1968), the infection can have severe manifestations as: pneumonia, peripheral edema, pleural effusion and atypical rash. Measles are one of the most contagious infectious diseases. The virus spreads through droplets emanating from the respiratory tract of infected persons or by direct contact. The incidence of Measles has declined since the introduction of vaccination programs.
The IMMUNOLAB Measles IgA antibody test kit is based on the principle of the enzyme immunoassay (EIA). Measles antigen is bound on the surface of the microtiter strips. Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A binding between the IgA antibodies of the serum and the immobilized Measles antigen takes place. After a one hour incubation at room temperature, the plate is rinsed with diluted wash solution, in order to remove unbound material. Then ready-to-use anti-human-IgA peroxidase conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB) solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the wells. The color development is terminated by the addition of a stop solution, which changes the color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The concentration of the IgA antibodies is directly proportional to the intensity of the color.
- Altintas, DU. et al. The modification in measles vaccination age as a consequence of the earlier decline of transplacentally transferred antimeasles antibodies in Turkish infants. Eur. J. Epidemiol., 12(6): 647-8 (1996).
- Bayas, JM. et al. Susceptibility to measles, rubella and parotitis in young adults. Med. Clin. (Barc), 106(15): 561-4 (1996).
- Bouche, F. et al. Immunosorbent assay based on recombinant hemagglutinin protein produced in a high-efficiency mammalian expression system for surveillance of measles immunity. J. Clin. Microbiol., 36(3): 721-6 (1998).
- Chiu, HH. et al. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. J. Med. Virol., 51(1): 32-5 (1997).
- Dagan, R. et al. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Pediatr. Infect. Dis. J., 14(11): 965-9 (1995).
- De Souza, VA. et al. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J. Med. Virol., 52(3): 275-9 (1997).
- Duvdevani, P. et al.: Determination of immunity to measles virus in young adults: comparative evaluation of a commercial enzyme immunoassay and the hemagglutination inhibition techniques. Clin. Diagn. Virol., 7(1): 1-6 (1996).
- Johnson, CE. et al. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years. Pediatr. Infect. Dis. J., 15(8): 687-92 (1996).
- King, SM. et al. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant., 17(4): 633-6 (1996).
- Matter, L. et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after the introduction of MMR mass vaccination. Eur. J. Epidemiol., 13(1): 61-6 (1997).
- Mendelson, E. et al. Measles immunity and response to revaccination of a young adult population in Israel. J. Med. Virol., 50(3): 249-53 (1996).
- Metintas, S. et al. A serological survey of measles vaccine in a rural region of Eskisehir in Turkey. Public Health, 111(6): 373-6 (1997).
- Narita, M. et al. Measles virus-specific immunoglobulin G subclass response in serum and cerebrospinal fluid. Clin. Diagn. Virol., 8(3): 233-9 (1997).
- Nates, S. et al. Immunoglobulin M antibody response to measles virus following natural virus infection, primary vaccination, and reexposure to the virus. Viral Immunol., 10(3): 165-73 (1997).
- Pison Garces, FJ. et al. Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine. Aten. Primaria, 15(4): 235-7 (1995).
- Vardas, E. et al. Measles virus transmission from infected to immune individuals–implications for measles control and elimination. S. Afr. Med. J., 87(12): 1709 (1997).